Portuguese 
English 
Spanish 
3 min of reading 
9 comments 
Cimed Allocates an Investment of R$ 3.5 Billion to Expand Production and Considers a New Factory in the North or Northeast, in Addition to Investing in Technology.
A Cimed, one of the leaders in the Brazilian pharmaceutical sector, revealed an ambitious expansion plan involving an investment of R$ 3.5 billion over the next five years. The central goal is to significantly increase its production capacity and consolidate its market presence in consumer goods. The company’s president, João Adibe, emphasized that Cimed aims to position itself as the “Brazilian Procter & Gamble,” a comparison that demonstrates the magnitude and ambition of the strategy. The company, known for its robust operation in the pharmaceutical sector, is preparing for a major leap, with investments focused on expanding its facilities and on technological innovation to enhance its performance in the national market.
Increase in Cimed’s Production Capacity
Of the total amount of R$ 3.5 billion, the majority, R$ 2 billion, will be allocated to expanding Cimed’s production capacity.
Currently, the company has two factories in Minas Gerais and has a production capacity of 50 million units per month.
-
At 625 meters above the ground and with a span of 1,420 meters between mountains, China inaugurated the highest bridge in the world — and the 2-hour journey now takes 2 minutes.
-
While in Brazil a 10-story building takes 2 years to complete, in China a company stacks pre-fabricated modules and raises the entire building in just 28 hours and 45 minutes.
-
China inaugurates a 24 km monster that is a bridge, tunnel, and museum at the same time — and 90,000 cars pass through it every day.
-
New J.Macêdo factory receives an investment of R$ 300 million, expands pasta production in the Northeast, creates jobs, and boosts the economy in Ceará.
With the new investment, the goal is to double this capacity to 100 million units per month over the next five years.
This increase will allow Cimed to expand its product offerings, which include generic drugs and consumer goods.
Currently, the company’s production is divided between generic medications, which represent 60% of the volume, and consumer goods, which make up the other 40%.
Among the highlights in the consumer goods segment are the Lavitan vitamin supplement line and Carmed lip balms.
In addition to increasing production, Cimed is considering the installation of a third factory, which could be located in the North or Northeast regions of Brazil.
This geographical expansion is part of a diversification strategy and aims to broaden the company’s distribution reach.
Currently, Cimed covers 90,000 points of sale through 27 distribution centers across the country. The new factory would further strengthen the company’s presence in the national market.
Investments in Technology and Efficiency
Cimed has also earmarked R$ 200 million to improve efficiency and management of its operations.
These resources will be used to implement artificial intelligence tools and Salesforce sales management software.
The adoption of these technologies is seen as crucial for optimizing processes and improving service to the pharmaceutical retail sector, enabling more efficient and agile management.
In addition, Cimed has a portfolio of 600 products, which continues to grow. Recently, the company expanded its Carmed product line in partnership with Fini.
This line generated R$ 1 billion in revenue for pharmacies since last year, highlighting Cimed’s strategy to diversify its offerings and reach different consumer segments.
Distribution Strategy and Acquisitions
Despite the continuous expansion, Cimed has decided not to invest in direct sales to consumers.
According to João Adibe, the company’s priority is to strengthen its relationships with retailers. “My focus is to deliver to retail,” Adibe stated, emphasizing that Cimed will continue to invest in expanding its distribution network to better serve its business partners.
The attempt to acquire Jequiti, a cosmetics company from Grupo Silvio Santos, was dismissed by Cimed.
However, João Adibe stated that the company remains attentive to new acquisition opportunities that could complement its portfolio and strengthen its market position.
Cimed’s strategy to grow in the consumer goods market is compared by experts to the movement of Hypermarcas, which sought to diversify its portfolio before consolidating as Hypera Pharma, refocusing on medications.
Cimed’s Ambitious Goals and Future Growth
Cimed has set ambitious goals for the coming years. The company aims to reach a revenue of R$ 5 billion in 2025 and evolve to R$ 10 billion by 2029.
In 2023, the company’s net revenue was R$ 2.25 billion, representing a 15.9% increase compared to the previous year.
These results demonstrate Cimed’s commitment to growth and innovation in the pharmaceutical and consumer goods sector.
Cuidado!!! Investe, faz promessa e depois fecha a fábrica, como aconteceu em SC.
Pernambuco está se consolidando como um polo farmacêutico. Acho muito dificil não instalarem a nova fábrica por lá
Uma estratégia bem pensada, Pernambuco seria um estado bem situado nessa estratégia, temos localização, porto de suape, Polo farmacêutico e ligações com os estados nordestino. Hora de se conversar com os órgãos competentes.